TIMP-1、MMP-9在乳腺癌患者术前血清中的表达与临床病理特征的关系

目的：探讨血清基质金属蛋白酶MMP-9及其抑制剂TIMP-1在乳腺癌患者术前血清中的表达与临床病理特征的关系。方法：收集52例乳腺肿瘤患者术前血清，通过ELISA方法检测9例良性肿瘤患者与43例浸润性乳腺癌患者血清中MMP-9和TIMP-1的含量并计算二者比值，用免疫组化技术检病变组织中MMP-9和TIMP-1的表达。结果：与良性肿瘤相比，MMP-9与TIMP-1蛋白表达在术前乳腺癌患者血清中的表达均有显著性升高；对于乳腺癌患者而言，术前血清中MMP-9、TIMP-1的浓度与MMP-9/TIMP-1的比值与患者的TNM分期、肿瘤长度、淋巴结累及之间具有统计学差异，但与患者的年龄、分级无关；MMP-9和TIMP-1二者的浓度之间并无相关性；血清中MMP-9和TIMP-1的浓度与组织蛋白的表达呈正相关。结论：检测术前血清中MMP-9与TIMP的表达有潜力作为良恶性肿瘤鉴别的指标之一；监测乳腺癌患者血清MMP-9和TIMP-1的表达有助于确定肿瘤的转移情况，并对预后的判断具有参考意义。

Clinical significance of the expression of TIMP-1 and MMP-9 in the serum of breast cancer patients before surgery

Objective To investigate the clinical significance of the expression of TIMP-1 and MMP-9 in the serum of breast cancer patients before surgery. Methods The serum 52 patients with breast tumor patients were collected before surgery. ELISA and Immunohistochemistry were used respectively to determine the expression of MMP-9 and TIMP-1 in serum and tu-mor tissues of 9 patients with benign tumor and 43 breast cancer patients. The ratio between MMP-9 and TIMP-1 was also cal-culated. Results Compared with patients with benign tumor, breast cancer patients showed significantly elevated serum levels of MMP-9, TIMP-1 and MMP-9/TIMP-1;statistical difference of MMP-9, TIMP-1 and MMP-9/TIMP-1 was found in the TNM stage, tumor length and Lymph node involvement, but not in histological grading and age;the serum concentrations of MMP-9 and TIMP-1 showed no relevance;the serum concentration of MMP-9 and TIMP-1 was positively correlated with that in tumor tissues. Conclusion The detection of MMP-9 and TIMP-1 in serum of breast tumor patients before surgery has potential to identify cancer from benign tumor;monitoring the concentration of MMP-9 and TIMP-1 can help to confirm tumor metastasis and judge prognosis.